Paolo Tarantino, MD

Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.

Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.

Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.

Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.

Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.

Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.

A new drug shows promise in treating triple-negative breast cancer, significantly improving survival rates and offering hope for better treatment options.

Discover how novel antibody-drug conjugates effectively target brain metastases, offering hope for reducing CNS recurrences in cancer patients.

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Paolo Tarantino, MD, discusses the evolving role of trastuzumab plus pertuzumab and chemotherapy in HER2-positive breast cancer after DESTINY-Breast09.

Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

Paolo Tarantino, MD, discusses the expanding role of T-DXd in HER2-positive breast cancer.

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Paolo Tarantino, MD, the clinical impact of the KATHERINE trial in reshaping the post-surgical treatment algorithm for HER2+ breast cancer care.

Paolo Tarantino, MD, discusses considerations around the frontline treatment of metastatic HER2-positive breast cancer.

Paolo Tarantino, MD, discusses the evolving role of anthracycline- and taxane-based regimens in HER2-positive breast cancer.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.